Rheumatology

Since the 1990s, outcomes for patients with RA have steadily improved over time, with the treatment target for patients evolving from symptomatic relief…

The aim of this symposium was to familiarise participants with the IL-23 pathway and the rationale for targeting this pathway in PsA…

The field of immunometabolism is a rapidly expanding area of research that centres around understanding the interrelationship between immunological and…

Osteoporosis is a systemic skeletal disease characterised by microarchitectural deterioration and high fragility of bone tissue, resulting in low bone…

Although aPL are reported in 1–5% of the general population,2 only a minority of these individuals will develop the clinical manifestations of APS. The incidence of APS…

Psoriatic arthritis (PsA) belongs to the group of diseases known as spondyloarthritis (SpA). The impact of PsA is not limited to just skin and joints…

Adalimumab is a recombinant fully human monoclonal antibody (IgG1 type) targeting soluble and transmembrane TNF. AbbVie’s bio-originator adalimumab…

Apremilast (APR) is a small molecule phosphodiesterase-4 inhibitor that is used in the treatment of psoriasis (PsO) and psoriatic arthritis (PsA)…